key: cord-0814738-dm0bxyut
authors: Liskova, Alena; Samec, Marek; Koklesova, Lenka; Samuel, Samson M.; Zhai, Kevin; AL-Ishaq, Raghad Khalid; Abotaleb, Mariam; Nosal, Vladimir; Kajo, Karol; Ashrafizadeh, Milad; Zarrabi, Ali; Brockmueller, Aranka; Shakibaei, Mehdi; Sabaka, Peter; Mozos, Ioana; Ullrich, David; Prosecky, Robert; La Rocca, Giampiero; Caprnda, Martin; Büsselberg, Dietrich; Rodrigo, Luis; Kruzliak, Peter; Kubatka, Peter
title: Flavonoids against the SARS-CoV-2 induced inflammatory storm
date: 2021-02-25
journal: Biomed Pharmacother
DOI: 10.1016/j.biopha.2021.111430
sha: 9f59a560f7e7274db4391cbc815c2799ab95b5de
doc_id: 814738
cord_uid: dm0bxyut

The disease severity of COVID-19, especially in the elderly and patients with co-morbidities, is characterized by hypercytokinemia, an exaggerated immune response associated with an uncontrolled and excessive release of proinflammatory cytokine mediators (cytokine storm). Flavonoids, important secondary metabolites of plants, have long been studied as therapeutic interventions in inflammatory diseases due to their cytokine-modulatory effects. In this review, we discuss the potential role of flavonoids in the modulation of signaling pathways that are crucial for COVID-19 disease, particularly those related to inflammation and immunity. The immunomodulatory ability of flavonoids, carried out by the regulation of inflammatory mediators, the inhibition of endothelial activation, NLRP3 inflammasome, toll-like receptors (TLRs) or bromodomain containing protein 4 (BRD4), and the activation of the nuclear factor erythroid-derived 2-related factor 2 (Nrf2), might be beneficial in regulating the cytokine storm during SARS-CoV-2 infection. Moreover, the ability of flavonoids to inhibit dipeptidyl peptidase 4 (DPP4), neutralize 3-chymotrypsin-like protease (3CL(pro)) or to affect gut microbiota to maintain immune response, and the dual action of angiotensin-converting enzyme 2 (ACE-2) may potentially also be applied to the exaggerated inflammatory responses induced by SARS-CoV-2. Based on the previously proven effects of flavonoids in other diseases or on the basis of newly published studies associated with COVID-19 (bioinformatics, molecular docking), it is reasonable to assume positive effects of flavonoids on inflammatory changes associated with COVID-19. This review highlights the current state of knowledge of the utility of flavonoids in the management of COVID-19 and also points to the multiple biological effects of flavonoids on signaling pathways associated with the inflammation processes that are deregulated in the pathology induced by SARS-CoV-2. The identification of agents, including naturally occurring substances such as flavonoids, represents great approach potentially utilizable in the management of COVID-19. Although not clinically investigated yet, the applicability of flavonoids against COVID-19 could be a promising strategy due to a broad spectrum of their biological activities.

The ongoing COVID-19 pandemic, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is currently one of the most discussed research topics worldwide [1] . The clinical manifestation of COVID-19 occurs after an incubation period of approximately 5 to 7 days and usually includes cough, fever, fatigue, headache, diarrhea, dyspnoea, and/or lymphopenia [2] . Most patients are asymptomatic or experience only mild to moderate symptoms. However, some patients may develop respiratory failure, acute respiratory distress syndrome (ARDS), or multiple organ failure [1, 3] . Advanced age and comorbidities such as diabetes, cardiovascular disease, hypertension, chronic kidney disease, and chronic obstructive pulmonary disease are highly associated with increased risk of severe course of COVID-19. Complications of severe COVID-19 includes ARDS, septic shock, coagulation dysfunction, metabolic acidosis, cardiac arrhythmia, kidney damage, liver dysfunction, heart failure, or secondary infections [2] . There is ample evidence that lung damage and multiple organ failure in COVID-19 result from systemic hyper-inflammation [1] . Similar to patients with SARS-CoV and MERS-CoV, the subgroup of COVID-19 patients with severe disease have a high levels of serum ferritin, D -dimer, fibrinogen, C-reactive protein, interleukin 6 (IL-6) and procalcitonine and are in increased risk of thrombosis and disseminated intravascular coagulation. These clinical and laboratory traits are linked to hyper-inflammation and are associated with macrophage activation syndrome [3] . Therefore, the identification of relevant anti-inflammatory agents applicable to COVID-19 patients could support strategies to overcome the current pandemic [1] . Reducing uncontrolled inflammation should be a therapeutic strategy, especially in patients with exaggerated immune response demonstrated by over-production of proinflammatory mediators also known as a cytokine storm. Cytokine hyper-production is frequently followed by the development or worsening of acute respiratory failure, acute cardiac damage, or multiple organ failure [2] . Recently, the J o u r n a l P r e -p r o o f therapeutic use of naturally occurring phytochemicals has been revived, building on the traditional use of herbs for medicinal purposes [4, 5] . Flavonoids are secondary plant metabolites with a polyphenolic structure [6] that exhibit a wide range of biological effects, including anti-viral, anti-inflammatory, and immunomodulatory activities [7] [8] [9] [10] [11] [12] . In addition, flavonoids are relatively cheap and environmentally-friendly substances with minimal or no side effects [7, 8] . During the pandemic that limits people's lives worldwide, it is necessary to investigate all potential treatment options for COVID- 19 . Flavonoids, which are among the most important plant substances found in nature, might advance the treatment of excessive inflammation in COVID-19.

The primary immunogenic components of coronaviruses are spike glycoproteins that bind to host cells' receptors to enter them. The human receptor of SARS-CoV-2, angiotensinconverting enzyme-2 (ACE-2), is intensely expressed on the surface of alveolar epithelial type II, renal, cardiac, intestinal, endothelial, and brain cells, which is in a consistency with target organs of COVID-19 [3, 13] . ACE-2 is crucial for the entry and replication of SARS-CoV-2;

nevertheless, once attached, viral translocation and replication is followed by depletion of membrane ACE-2 [14] . However, the role of ACE-2 is to cleave the angiotensinII (AngII) into angiotensin1-7 (Ang1-7) [15] . Therefore, the binding of SARS-CoV-2 prevents the production of anti-inflammatory Ang1-7 and leads to the accumulation of proinflammatory

AngII. This mechanism is believed to be crucial in the pathogenesis of acute lung injury (ALI) in COVID-19 [16] . The protective effects of ACE-2 on ALI were observed in animal models; after infection by SARS-CoV, these injuries were more severe in mice with inactivated ACE-2 [17] . Dipeptidyl peptidase 4 (DPP4) has also been suggested as a co-J o u r n a l P r e -p r o o f receptor for SARS-CoV-2 [18, 19] . However, the evidence of a potential role of DPP4 in COVID-19 is still unclear. While Pitocco et al. have not so far supported the inhibition of DPP4 as a credible approach to mitigate COVID-19 [20] , other authors discuss the potential role of DPP4 as a target of therapeutic strategies in the pathology of SARS-CoV-2 [19, 21] . As is shown in Figure 1 [18, 19, 22] , the primary route of SARS-CoV-2 transmission includes direct contact through droplets of saliva or discharge from the respiratory tract when a person sneezes or coughs. After the binding of spike glycoprotein to ACE-2 receptor on the cell surface, SARS-CoV-2 enters the cell, releases RNA genome, and replicates [3] . When the cell is invaded by many viral particles and the viral load is high, the whole protein synthesis apparatus is dedicated to the replication of the virus. The new viral particles are assembled and released by exocytosis and the cell is up to the death by apoptosis or as a result of energetic-metabolic chaos. The released copies of the virus spread and infect other cells and organs in a chain expansion. Eventually, an inflammatory reaction develops in tissues with many dead cells, initially in the lungs and then systematically (lymph, blood, immune system, coagulation, liver, kidney) while the reaction can be clinically severe, especially in patients with co-morbidities [13] .

After the recognition of viral antigens by the immune system, antigen-presenting cells present viral antigens to natural killer (NK) cells and CD8-positive cytotoxic T-cells, which activate innate and adaptive immunity leading to the production of proinflammatory cytokines and chemokines [3] . Although the appropriate cytokine release is crucial for the defense against viral infection, an aberrant immune response can lead to organ injury [1] . Cytokines are secreted proteins with specific effects on the development, differentiation, and regulation of immune cells [23] . The immune activation by SARS-CoV-2 infection [24] , especially in the elderly or co-morbid patients [25] , can become so intense that it may cause deregulated inflammatory processes and uncontrolled systemic inflammatory responses, also known as a J o u r n a l P r e -p r o o f cytokine storm [24] . The cytokine storm, which has also been observed in other viral diseases (such as influenza, MERS, and SARS) is defined as an exaggerated immune response   demonstrated by the overproduction of proinflammatory cytokines such as IL-6, tumor necrosis factor-alpha (TNF-α), and IL-1β. Currently, there is a clear correlation between elevated pro-inflammatory cytokines as a surrogate marker of cytokine storm and the severity of COVID-19 as well as unfavorable outcomes in hospitalized patients. Elevated IL-6 is recognized as one of the most important marker of unfavorable outcome [1, 23] . The cytokine storm could lead to thrombotic events, ARDS, multiple organ failure, and death [3, 26] . The direct cause of death from acute COVID-19 includes cytokine storm-induced damage predominantly to the lungs. However, other organs, including heart, kidney, and liver are also affected. ARDS is characterized by the cytokine storm as one of its main features [24] .

Therefore, the over-stimulated immune response may cause more damage to host cells than the foreign invader (SARS-CoV-2) [23] . Other immunologic features of COVID-19 include a lower level of T-lymphocytes, NK cells, and regulatory T-cells in patients with severe manifestation of the disease. On the contrary, an increased level of monocytes and macrophages in COVID-19 patients may explain the elevation of proinflammatory cytokines associated with the cytokine storm [3] . The above-discussed immunologic features of COVID-19 are illustrated in Figure 2 [1, 3, 23, 24] . Also, the normal gut microbiota can maintain immune response to a viral infection and improve respiratory symptoms [18] .

Elevated levels of cytokines and inflammatory markers including IL-6, IL-10, IL-1β, and D -dimer have been observed in severely ill COVID-19 patients compared to those with moderate symptoms [1] . Also, the examination of bronchoalveolar lavage fluid revealed the excessive release of chemokines, including C-X-C motif chemokine ligand 10 (CXCL10) and J o u r n a l P r e -p r o o f monocyte chemo-attractant protein-1 (CCL2), due to SARS-CoV-2 infection [26] . Table 1 [27-31] provides a detailed overview of the clinical features of COVID-19 patients associated with the inflammatory chaos.

Inflammatory pathways associated with SARS-CoV-2 during innate immune response include toll-like receptors (TLRs), which represent a subfamily of pattern recognition receptors (PRR). PRR are capable to recognize viruses including SARS-CoV-2 in the extracellular milieu or endosomes and mediate the inflammatory signaling leading to the activation and production of inflammatory cytokines [23] . Another important inflammatory mediator of the SARS-CoV-2-related exaggerated immune response might be the inflammasome triggered by NLRP3 that also belong s to PRR family. It is expressed in various cell types, including innate immune, endothelial, lung epithelial, hematopoietic, kidney, or cardiac cells [32] . Another mediator of innate immune reaction to SARS-CoV-2 is the bromodomain-containing protein 4 (BRD4). It is an epigenetic reader of acetylated lysines belonging to the bromodomain and extra terminal domain (BET) family that play an important role in epithelial-driven and nuclear factor kappa B (NF-κB)-dependent innate inflammation during viral infection [1] . Furthermore, respiratory viral infections are associated with inflammatory processes and oxidative stress of the epithelium lining cells that activate the transcription factor nuclear factor erythroid-derived 2-related factor 2 (Nrf2), which protects cells from oxidative damage and inflammation. The severity of COVID-19

disease is related to pre-existing conditions, including impaired immune responses, obesity, or age. These conditions are associated with decreased Nrf2 levels [25] .

J o u r n a l P r e -p r o o f

Based on the known mechanisms of SARS-CoV-2 infection, substances with potentially beneficial effects may act at various stages such as preventing the binding of the virus to the receptors or inhibiting the function of the receptor, suppressing viral replication, helping cells to resist viral attack via inhibition of cytotoxicity processes (potentially slowed down by natural antioxidants), and blocking the virus spread in the body [13] . Moreover, due to the association between over-inflammation or exaggerated immune response and SARS-CoV-2 infection, the cytokine is necessary to be early identified and appropriate anti-inflammatory treatment must be applied. Corticosteroids are currently anti-inflammatory agents with most solid evidence of benefit in the treatment of COVID-19 [1] .

However, their applicability is still associated with many unknowns [1] . Notably, as SARS-CoV-2 mainly increases IL-6, and therefore the administration of corticosteroids acting against a wide range of cytokines might be excessive [26] . Therefore, in addition to the global targeting of inflammation, the neutralization of a single key inflammatory mediator is a currently evaluated therapeutical approach in COVID-19 management [33] . Anti-cytokine therapies such as IL-6, TNFα, and IL-1 cytokine antagonists are suggested to alleviate the hyper-inflammation associated with COVID-19 [23] . Potential treatment strategies targeting the cytokine storm in COVID-19 include the recombinant humanized anti-human IL-6 receptor monoclonal antibody tocilizumab. Nevertheless, the efficacy and safety of tocilizumab in COVID-19 patients needs to be evaluated in large samples and high quality studies and its benefits are yet to be established [26] . In addition, anti-TNF antibodies (infliximab, adalimumab) are suggested to modulate hyper-inflammation and cause a rapid decrease in proinflammatory cytokines in COVID-19 patients. As mentioned above, NLRP3

inflammasome plays a crucial role in the activation of IL-1β. Therefore, drugs targeting NLRP3 inflammasome and IL-1β are promising agents to mitigate hyper-inflammation and J o u r n a l P r e -p r o o f cytokine storm induced by NLRP3 inflammasome in severely ill COVID-19 patients [23] .

Other potential therapeutic strategies against COVID-19 include cytokine-adsorption device [26] , JAK inhibitors, chloroquine, hydroxychloroquine [27] , or interferon [34] . Despite the lack of any reported cases of COVID-19 patients treated with BRD4 inhibitors, these drugs can be also considered as potential candidates to ameliorate the excessive inflammation and cytokine storm associated with COVID-19 [1] . Nevertheless, before implementing antiinflammatory strategies in COVID-19 patients, it is highly important to balance the risks and benefits of specific therapeutic modalities due to the impairment of host immune system which might lead to secondary infections [27] .

Flavonoids are defined as important naturally occurring compounds with a phenolic structure [7] . Chemically, flavonoids are composed of fifteen-carbon skeleton that consists of two benzene rings connected through a pyrane ring [35] . Flavonoids are classified by their chemical structure, level of oxidation, and the pattern of the substitution of their heterocyclic pyrane ring also known as C ring. The classification of individual compounds within each class is based on the substitution of benzene rings (A and B rings) [7] . Table 2 provides an overview of the classification and food sources of flavonoids [7] [8] [9] [36] [37] [38] [39] [40] [41] .

Flavonoids are secondary plant metabolites responsible for their color, flavor, and are also related to plants' pharmacological activities. Flavonoids possess significant anti-bacterial, anti-oxidant, anti-cancer, anti-inflammatory, and immunomodulatory abilities [7, 8, 42] . In addition, flavonoids exert a strong anti-viral capacity in numerous pathologies [43] [44] [45] [46] . More importantly, flavonoids demonstrated anti-viral and immunomodulatory activities against coronaviruses [47] . Therefore, the anti-viral properties of flavonoids might be applicable also J o u r n a l P r e -p r o o f in the current COVID-19 pandemic. The potentially beneficial role of flavonoids or flavonoid-rich whole plants in COVID-19 pandemic is currently a widely discussed topic [48] [49] [50] [51] . One of the suggested targets of SARS-CoV-2 therapies is the ACE-2 receptor [52] .

The applicability of flavonoids is associated with the SARS-CoV-2 spike-protein that engages ACE-2 receptors to entry into host cells as was demonstrated by bioinformatics and molecular docking in case of tea flavonoids, especially epigallocatechin-3-gallate (EGCG) and

theaflavin gallate [53] , fisetin, quercetin, kaempferol [54] , quercetin, luteolin, or naringenin [55] . Moreover, the biological activity of flavonoids predetermines them to be effective also in terms of the modulation of inflammatory and immune pathways of SARS-CoV-2associated pathology.

The anti-inflammatory and immunomodulatory properties of flavonoids are well- [23] . Generally speaking, flavonoids can modulate the production of inflammatory mediators. Luteolin inhibited IL-1β-induced inflammation in rat chondrocytes [56] . Similarly, apigetrin, a glucoside conjugate of apigenine [57] , reduced inflammatory factors including ILlβ, TNF-α, IL-6, and VEGF in mice with acute otitis media [58] . Also, Smilax campestris Therefore, a significant benefit of flavonoids is associated with their potent immunomodulatory properties [11, 62, 65] .

Based on the immunomodulatory properties of flavonoids discussed above, we can assume their significant effects on the production of proinflammatory cytokines also within COVID-19. Despite the high affinity to the spike protein, helicase and protease sites on ACE-2 demonstrated in in silico studies, the flavonoid-based phytomedicine caflanone also exhibited the ability to inhibit the production of cytokines including IL-1β, IL-6, IL-8, Mip-1α, TNF-α [47] . Moreover, Bellavite and Donzelli [13] recently discussed the nutraceutical properties of citrus fruits, primarily focusing on its flavonoid component hesperidin as a potential substance against SARS-CoV-2 due to its anti-viral, anti-oxidant, and inflammationmodulatory activities [13] . Hesperidin ameliorated altered level of inflammatory mediators in J o u r n a l P r e -p r o o f ischemia/reperfusion-induced kidney injury in rats [66] and also triggered anti-inflammatory responses resulting in a decreased level of IL-33 and TNF-α in mice co-treated with hesperidin and LPS [67] . Nevertheless, the hypothetical role of citrus flavonoid hesperidin against COVID-19 requires corroboration in further pre-clinical, epidemiological, and clinical studies [13] .

Moreover, vascular endothelial activation has a crucial role in the excessive cytokine production leading to the cytokine storm and severe pathologies in infectious diseases such as SARS or COVID-19. Therefore, rhamnocitrin, a flavonoid extracted from Nervilia fordii, which has been identified as a potent inhibitor of endothelial activation, might be suggested as a potential modulator of cytokine storm in the management of these diseases [68] .

Notably, the traditional Chinese medicine (TCM) with its main active ingredients including flavonoids (such as quercetin, kaempferol, luteolin, baicalein, naringnein, and wogonin) could also exert beneficial effects in the management of COVID-19 via the inhibition of viral adsorption and replication as well as the regulation of inflammatory mediators, anti-inflammatory, and immune-regulatory effects to prevent cytokine storm and to protect the target organs [69] . Indeed, Niu et al. [70] recently evaluated chemical constituents of three TCM formulas that were proven to be effective in COVID-19. Eventually, the network pharmacology research revealed decreased IL-6 through several TCM compounds, including but not restricted to quercetin, luteolin, and rutin. These observations suggest the positive association between TCM efficiency in the prevention and rehabilitation of at-risk COVID-19 [70] . Similarly, other TCM formula, which includes quercetin among others, could inhibit COVID-19 through ACE2 downregulation [71] . Moreover, Table 3 

Flavonoids demonstrated reasonable effects in the modulation of inflammatory mediators or signaling cascades including TLRs and NLRP3 inflammasomes (Table 4 ) [41, [79] [80] [81] [82] [83] [84] [85] [86] [87] .

Altogether, these results highlight flavonoids' capacity to target inflammatory processes associated with TLRs and NLRP3 inflammasome, the deregulation of which is discussed also in terms of SARS-CoV-2 pathology. Therefore, it can be assumed that flavonoids exert significant anti-viral and immunomodulatory effects mediated through TLRs or NLRP3 J o u r n a l P r e -p r o o f inflammasomes in COVID-19 patients while these effects need to be precisely evaluated in well-defined pre-clinical and clinical studies.

As mentioned above, the transmembrane E protein of SARS-CoV-2 has been recently demonstrated to bind to BRD4 while its recruitment by NF-κB activates proinflammatory signaling [1] . Importantly, fisetin and amentoflavone are putative ligands of BRD4 and amentoflavone can establish contacts with non-canonical residues for BET inhibition [88] .

Moreover, Yokoyama [89] recently discussed the structural and thermodynamic characteristics of isoliquiritigenin interactions with BRD4 and suggested it as a novel template for BDR inhibitors [89] . Hence, BRD4 inhibition represents another approach potentially applicable to overcome COVID-19 associated inflammatory chaos.

The Nrf2-response has been recently demonstrated to be suppressed in COVID-19 patient It can therefore be hypothesized that flavonoids could decrease the severity of SARS-CoV-2 via the activation of Nrf2 and subsequent modulation of inflammatory and immune processes [25] .

The dual impact of ACE-2 in COVID-19 is associated with its ability to convert AngII to Ang1-7, thus counteracting the inflammatory action of AngII [77] . The attachment of SARS-CoV-2 spike protein to ACE-2 is followed by down-regulation of ACE-2 through its intracellular binding site and then an increase in the level of AngII and augmentation of AngII/AT1R axis activation. Increased production of AngII and activation of angiotensin II receptor type 1 (AT1R) are processes associated with proinflammatory response. The activation of NF-κB by AngII also leads to the production of TNF-α, IL-6, IL-1β. AT1R activation is followed by the regulation of mitogen-activated protein kinase (MAPK) by

AngII, which also affects the release of cytokines (TNF-α, IL-1). Furthermore, the activation of the renin-angiotensin-aldosterone system (RAAS) can be associated with proinflammatory responses through AT1R in the kidney and vascular system. In fact, increased circulatory levels of AngII have been observed in COVID-19 patients with the association of its plasma level and lung injury [16] . However, the ACE-2-cleaved protein Ang1-7 is hypothesized to possess beneficial effects on immune regulation and its low expression during SARS-CoV-2 infection can be associated with COVID-19 severity. The antagonist effects of AngII-derived pathway is associated with the binding of Ang1-7 to the mitochondrial assembly (Mas) receptor and consequent decrease in proinflammatory cytokine production (TNF-α, IL-6) [78] . Therefore, the binding of SARS-CoV-2 to ACE-2 decreases its anti-inflammatory Ang1-7 production and promotes the accumulation of proinflammatory AngII [16] .

In 1982, Agarwal demonstrated anti-inflammatory effects of a flavonoid nepitrin that could be mediated through its anti-angiotensin action [101] . More recently, in hypertensive rats models, high levels of AngII were attenuated by hesperidin [102] and RAS activation was inhibited by tangeretin [103] . Similarly, kaempferol exerted inflammation-inhibitory effects mediated by a decrease in AngII-induced collagen accumulation in cardiac fibroblasts [104] . A precise analysis of the effects of ACE-2 on the overall course of SARS-CoV-2 pathogenesis may contribute to the identification of key agents, potentially even among flavonoids, targeting the discussed ACE-2 and related signaling mechanisms.

Other mechanisms that could potentially be modulated by flavonoids in COVID-19

include the inhibition of DPP4, the neutralization of 3CL pro , or the effects on gut microbiota.

Dipeptidyl peptidase 4

In addition to ACE-2, recently suggested interaction between SARS-CoV-2 and dipeptidyl peptidase 4 (DPP4) as a co-receptor could lead to the development of novel therapeutic COVID-19 strategies. DPP4 is a ubiquitous membrane-bound aminopeptidase with multiple roles in metabolism, nutrition, and the endocrine and immune system [105] . A large interface was observed between the SARS-CoV-2 spike glycoprotein and DPP4 using a docked complex model. The capacity of DPP4 to cleave numerous substrates, such as chemokines or growth factors, is associated with its ability to regulate numerous physiological processes [18] and diseases of the immune system. DPP4 is expressed on epithelia and endothelia of the systemic vasculature, lung, small intestine, kidney, and heart. Accordingly, DPP4 distribution may contribute to the virus's entry through the respiratory tract and may also facilitate the development of cytokine storm and immune-pathologies associated with fatal COVID-19 consequences [19] . Therefore, some investigators suggest the inhibition of DPP4 as a therapeutic strategy to slow the progression of COVID-19 or to hamper cytokine storm and inflammation [18, 19] . DPP-4 inhibitors, generally known as anti-diabetic drugs, may possess immunomodulatory functions and could be beneficial in inflammatory diseases [106, 107] and could act beneficially also in COVID-19 patients through the reduction of inflammation [108] . Natural compounds, including flavonoids such as EGCG also target DPP4 [109] [110] [111] [112] . Indeed, citrus flavonoids [113] , epicatechin [114] , and chrysin [115] were demonstrated to be potent DPP4 inhibitors. Overall, flavonoids may represent a source of DPP4 inhibitors with potential efficacy against COVID-19.

3-chymotrypsin-like protease (3CL pro ) is a non-structural protein of coronaviruses. The Therefore, the neutralization of 3CL pro can avert viral maturation and restore the natural immune response [18] . As in the case of SARS-CoV [116, 117] and MERS-CoV [118] , the promising role of flavonoids has been recently suggested also in SARS-CoV-2 pathology.

Interestingly, quercetin has been demonstrated as a potent inhibitor of SARS-CoV-2 3CL pro in vitro and can be considered a proper candidate for further optimization and development [119] . Similarly, the docking study revealed quercetin, scutellarin, and myricetin as potent candidates to target 3CL pro [120] . Despite quercetin's promising efficiency in COVID-19

targeting 3CL pro , its anti-viral properties may be challenged by its poor oral bioavailability. approach [122] . Thus, the neutralization of 3CL pro by flavonoids to restore immune response represents another potential strategy against COVID-19.

Despite that SARS-CoV-2 is associated with acute respiratory syndrome, there are also gastrointestinal manifestation that may precede respiratory events. Therefore, due to the capacity of normal gut microbiota restoration to maintain immune response to viral diseases and improve respiratory symptoms, the prebiotic properties of polyphenolic compounds may represent a therapeutic strategy for COVID-19, primarily due to the possibility to affect the J o u r n a l P r e -p r o o f gut microbiota of patients [18] . Flavonoids can modulate intestinal immune function through the modulation of T-cell differentiation, alteration of gut microbiota as well as the regulation of cytokines [123, 124] . Also, Estruel-Amades [125] demonstrated the immunomodulatory activity of hesperidin on gut-associated lymphoid tissue and reinforced its prebiotic role [125] . Hence, the restoration of the immune responses through gut microbiota may potentially support the organism to overcome COVID-19.

Above all, flavonoids modulate the synthesis or activity of a plethora of inflammatory mediators and immunomodulatory signals [51, 74, 113, 114, 118, 121, 123, 126, 127] . However, pre-clinical evidence might be limited by the utilization of non-physiological concentrations in in vitro models while flavonoids are extensively metabolized in vivo [126] . Low bioavailability of flavonoids can limit or hinder their activity. Generally speaking, the bioavailability of flavonoids is affected by several factors including molecular weight, glycosylation, or metabolic conversion [128] . The metabolism of flavonoids occurs in small and large intestine, and liver. Also, the absorption, distribution, and metabolism of flavonoids and their circulating concentrations, elimination, and tissue exposure are also affected by age, sex, genotype, habitual diet, prescribed medicine, and gut microbiome [7] . Gut microbiota plays an essential role in the metabolism of flavonoids [129] . However, some metabolites were observed to paradoxically exert more robust physiological functions than their precursors [7] . Nevertheless, the increase in flavonoids bioavailability as well as the safety evaluation of their application are the goals of ongoing research [7, 9, [130] [131] [132] . Furthermore, human studies are necessary to clarify the anti-inflammatory properties of flavonoids [126] . Explanatory notes: APC present viral antigens to NK cells and CD8-positive cytotoxic cells to activate innate and adaptive immunity and to produce proinflammatory mediators (cytokines) [3] . The immune activation might become so intense that it can lead to exaggerated immune response (cytokine storm) [1, 23] . The cytokine storm can result in the damage of lungs, kidneys, heart, and/or liver [24] . The immunologic features of COVID-19 include also lower levels of T-lymphocytes, NK cells, and regulatory T-cells in patients with severe disease

progression. An increased level of monocytes and macrophages in COVID-19 patients can also explain the elevation of proinflammatory cytokines [3] .

J o u r n a l P r e -p r o o f inflammasome [23] . The NLRP3 inflammasome is activated in response to AngII stimulation [32] . proinflammatory responses through AT1R in kidney and vascular system [16] . The ACE-2cleaved protein Ang1-7 bind to Mas that is followed by a decrease in proinflammatory cytokine production (TNF-α, IL-6) [78] . Therefore, the binding of SARS-CoV-2 to ACE-2 prevents the production of anti-inflammatory Ang1-7 and leads to the accumulation of proinflammatory AngII [16] .

J o u r n a l P r e -p r o o f Table 1 . Excessive levels of cytokines and chemokines in COVID-19 patients

The level of inflammation-associated molecules in COVID-19 patients  Reference  Increased IL-1B, IL-1RA, IL-7, IL-8, IL-9, IL-10, FGF, GM-CSF, IFNγ, G-CSF, IP10, MCP1, MIP1A, PDGF, TNFα, VEGF in COVID-19 patients  (among which IL-2, IL-7, IL-10, G-CSF, IP10 , MCP1, MIP1A, TNFα higher in severe patients) [27] Increased plasmatic concentration of IL-2, IL-7, IFN-γ, GCSF, IP-10, MCP1, MIP, and TNF-α in severe COVID-19 patients [28] Increased IL-6 in patients with ARDS who died in comparison with patients with ARDS who survived [29] Increased IL-6 in patients with pneumonia [30] Increased IL-6 associated with death [31] Abbreviations: ARDS, acute respiratory distress syndrome; FGF, fibroblast growth factor; G-CSF, granulocytecolony stimulating factor; GM-CSF, granulocyte-macrophage colony-stimulating factor; IFNγ, interferongamma; IL, interleukin; IP10, interferon-γ-inducible protein 10; MCP1, monocyte chemo-attractant protein 1;MIP, macrophage inflammatory proteins;MIP1A, macrophage inflammatory protein 1 alpha; PDGF, plateletderived growth factor; TNFα, tumor necrosis factor-alpha; VEGF, vascular endothelial growth factor. Suppression of the inflammatory storm and regulation of immune function. [72] Observed affinity between the core compounds of Dayuanyin (kaempferol, quercetin, 7-Methoxy-2-methyl isoflavone, naringenin, formononetin) and its target genes such as IL-6, IL1β, and CCL2.

Recognized and verified gene targets (including IL-6) and three components of Maxingyigan (quercetin, formononetin, luteolin). [73] The potential role of Maxingyigan in the prevention and treatment of COVID-19 could be based on its antiinflammatory and immunity-based actions including the activation of T-cells, lymphocytes, leukocytes, cytokinecytokine-receptor, and chemokine signaling pathways. Toujie Quwen granule

The potential role of Toujie Quwen granule and its key active ingredients (including quercetin, kaempferol, luteolin, and oroxylin A, among others) in the treatment of COVID-19 associated with the mechanisms that elevate immunity, suppress inflammatory stress, and regulate inflammatory responses among others. [74] Qing-Fei-Pai-Du decoction Observed immuno-regulatory, anti-inflammatory and multiorgan protective abilities (attributed to four compounds including also flavonoids baicalin and hesperidin and its targets) that could be applicable in COVID-19 management (thrombin and TLR signaling suggested as essential pathways of its anti-inflammatory effects). [75] Abbreviations: CCL2, monocyte chemo-attractant protein-1; IL, interleukin; TCM, Traditional Chinese medicine; TLR, Toll-like receptor. Suppression of NLRP3 inflammasome activation and serum IL-1β release.

[41]

Abbreviations: IL, interleukin; NF-κB, nuclear factor kappa B; TLRs, Toll-like receptors; TNFα, tumor necrosis factor

Targeting inflammation and cytokine storm in COVID-19

SARS-CoV-2 infection: The role of cytokines in COVID-19 disease

Cytokine storm in COVID-19: pathogenesis and overview of anti-inflammatory agents used in treatment

Historical review of medicinal plants' usage

Plant Natural Products for Human Health

Potential Role of Flavonoids in Treating Chronic Inflammatory Diseases with a Special Focus on the Anti-Inflammatory Activity of Apigenin

Flavonoids in Cancer Metastasis

Flavonoids in Cancer and Apoptosis

Implications of flavonoids as potential modulators of cancer neovascularity

Antitumor and immunomodulatory activities of total flavonoids extract from persimmon leaves in H 22 liver tumor-bearing mice

Immunomodulatory Effects of Flavonoids: Possible Induction of T CD4+ Regulatory Cells Through Suppression of mTOR Pathway Signaling Activity

Dietary Flavonoids for Immunoregulation and Cancer: Food Design for Targeting Disease

Hesperidin and SARS-CoV-2: New Light on the Healthy Function of Citrus Fruits

COVID-19 Infection, Inflammation, and Coagulopathy: Missing Pieces in the Puzzle

Linking ACE2 and angiotensin II to pulmonary immunovascular dysregulation in SARS-CoV-2 infection

COVID-19 cytokine storm: The anger of inflammation

Biological plausibility for interactions between dietary fat, resveratrol, ACE2, and SARS-CoV illness severity

Can phytotherapy with polyphenols serve as a powerful approach for the prevention and therapy tool of novel coronavirus disease 2019 (COVID-19)?

Dipeptidyl peptidase-4 (DPP4) inhibition in COVID-19

SARS-CoV-2 and DPP4 inhibition: Is it time to pray for Janus Bifrons?

The MERS-CoV Receptor DPP4 as a Candidate Binding Target of the SARS-CoV-2 Spike

The pivotal role of TMPRSS2 in coronavirus disease 2019 and prostate cancer

Targeting Cytokine Storm to Manage Patients with COVID-19: A Mini-Review

COVID-19: Pathogenesis, cytokine storm and therapeutic potential of interferons

Flavonoids Activation of the Transcription Factor Nrf2 as a Hypothesis Approach for the Prevention and Modulation of SARS

Cytokine Storm in COVID-19: The Current Evidence and Treatment Strategies

The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The Perspectives of clinical immunologists from China

Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China, The Lancet

Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease

Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

SARS-CoV-2 infection and overactivation of Nlrp3 inflammasome as a trigger of cytokine "storm" and risk factor for damage of hematopoietic stem cells

Cytokine-targeted therapy in severely ill COVID-19 patients: Options and cautions

Interferon-α2b Treatment for COVID-19

Therapeutic Potential of Flavonoids in Pain and Inflammation: Mechanisms of Action, Pre-Clinical and Clinical Data, and Pharmaceutical Development

A new antioxidant flavone glycoside from Scutellaria baicalensis Georgi

Isoliquiritigenin (ISL) and its Formulations: Potential Antitumor Agents

A comprehensive review on phytochemistry, pharmacology, and flavonoid biosynthesis of Scutellaria baicalensis

Cyanidin inhibits EMT induced by oxaliplatin via targeting the PDK1-PI3K/Akt signaling pathway

Cardamonin, a natural flavone, alleviates inflammatory bowel disease by the inhibition of NLRP3 via an AhR/Nrf2/NQO1 pathway

Flavonoids with Inhibitory Effects on NLRP3 Inflammasome Activation from Millettia velutina

Flavonoids as Anticancer Agents

Flavonoid from Carica papaya inhibits NS2B-NS3 protease and prevents Dengue 2 viral assembly

Antiviral activities of flavonoids isolated from the bark of Rhus verniciflua stokes against fish pathogenic viruses In Vitro

Antiviral and Antitumor Activity of Licorice Root Extracts

Elderberry flavonoids bind to and prevent H1N1 infection in vitro

Potential of Flavonoid-Inspired Phytomedicines against COVID-19

Applications, phytochemistry, pharmacological effects, pharmacokinetics, toxicity of Scutellaria baicalensis Georgi. and its probably potential therapeutic effects on COVID-19: a review

Could Sumac Be Effective on COVID-19 Treatment?

nCOV-19 peptides mass fingerprinting identification, binding, and blocking of inhibitors flavonoids and anthraquinone of Moringa oleifera and hydroxychloroquine

Flavonoids: A complementary approach to conventional therapy of COVID-19?

Natural Flavonoids as Potential Angiotensin-Converting Enzyme 2 Inhibitors for Anti-SARS-CoV-2

Epigallocatechin gallate and theaflavin gallate interaction in SARS-CoV-2 spike-protein central channel with reference to the hydroxychloroquine interaction: Bioinformatics and molecular docking study

Targeting SARS-CoV-2 spike protein of COVID-19 with naturally occurring phytochemicals: an in silico study for drug development

Structure-based drug designing for potential antiviral activity of selected natural products from Ayurveda J o u r n a l P r e -p r o o f against SARS-CoV-2 spike glycoprotein and its cellular receptor

Luteolin inhibits IL-1β-induced inflammation in rat chondrocytes and attenuates osteoarthritis progression in a rat model

Apigetrin inhibits adipogenesis in 3T3-L1 cells by downregulating PPARγ and CEBP-α

Apigetrin treatment attenuates LPS-induced acute otitis media though suppressing inflammation and oxidative stress

In vitro anti-inflammatory properties of Smilax campestris aqueous extract in human macrophages, and characterization of its flavonoid profile

Apigenin Ameliorates Dyslipidemia, Hepatic Steatosis and Insulin Resistance by Modulating Metabolic and Transcriptional Profiles in the Liver of High-Fat Diet-Induced Obese Mice

Potential Therapeutic Anti-Inflammatory and Immunomodulatory Effects of Dihydroflavones, Flavones, and Flavonols

Flavonoid-mediated immunomodulation of human macrophages involves key metabolites and metabolic pathways

Immunomodulatory potential of hesperetin and chrysin through the cellular and humoral response

Influence of Hesperidin on Systemic Immunity of Rats Following an Intensive Training and Exhausting Exercise

The role of plant-derived natural substances as immunomodulatory agents in carcinogenesis

The protective effect of hesperidin against renal ischemia-reperfusion injury involves the TLR-4/NF-κB/iNOS pathway in rats

In vivo and in vitro Evaluation of the Protective Effects of Hesperidin in Lipopolysaccharide-Induced Inflammation and Cytotoxicity of Cell

Rhamnocitrin extracted from Nervilia fordii inhibited vascular endothelial activation via miR-185/STIM-1/SOCE/NFATc3

Review on the potential action mechanisms of Chinese medicines in treating Coronavirus Disease 2019 (COVID-19)

Network pharmacology for the identification of phytochemicals in traditional Chinese medicine for COVID-19 that may regulate interleukin-6

Network Pharmacology Analysis to Identify Phytochemicals in Traditional Chinese Medicines That May Regulate ACE2 for the Treatment of COVID-19

Mechanism of Dayuanyin in the treatment of coronavirus disease 2019 based on network pharmacology and molecular docking

Theoretical Study of the Molecular Mechanism of Maxingyigan Decoction Against COVID-19: Network Pharmacology-based Strategy

Therapeutic mechanism of Toujie Quwen granules in COVID-19 based on network pharmacology

Systems pharmacological study illustrates the immune regulation, anti-infection, anti-inflammation, and multi-organ protection mechanism of Qing-Fei-Pai-Du decoction in the treatment of COVID-19

Dinkova-Kostova, Can J o u r n a l P r e -p r o o f Activation of NRF2 Be a Strategy against COVID-19?

The dual impact of ACE2 in COVID-19 and ironical actions in geriatrics and pediatrics with possible therapeutic solutions

COVID-19: Underlying Adipokine Storm and Angiotensin 1-7 Umbrella

Epigallocatechin-3-gallate ameliorates lipopolysaccharide-induced acute lung injury by suppression of TLR4/NF-κB signaling activation, Braz

Luteolin Targets the Toll-Like Receptor Signaling Pathway in Prevention of Hepatic and Adipocyte Fibrosis and Insulin Resistance in Diet-Induced Obese Mice

Anti-inflammatory effects of nobiletin on TLR4/TRIF/IRF3 and TLR9/IRF7 signaling pathways in prostate cancer cells

Toll-Like Receptor-Dependent Immunomodulatory Activity of Pycnogenol®

Flavonoids from Houttuynia cordata attenuate H1N1-induced acute lung injury in mice via inhibition of influenza virus and Toll-like receptor signalling

Flavonoids interfere with NLRP3 inflammasome activation

Scutellarin Suppresses NLRP3 Inflammasome Activation in Macrophages and Protects Mice against Bacterial Sepsis

Myricetin inhibits NLRP3 inflammasome activation via reduction of ROS-dependent ubiquitination of ASC and promotion of ROSindependent NLRP3 ubiquitination

Baicalin mitigates cognitive impairment and protects neurons from microglia-mediated neuroinflammation via suppressing NLRP3 inflammasomes and TLR4/NF-κB signaling pathway

Flavonoids as Putative Epi-Modulators: Insight into Their Binding Mode with BRD4 Bromodomains Using Molecular Docking and Dynamics

Structural and thermodynamic characterization of the binding of isoliquiritigenin to the first bromodomain of BRD4

SARS-CoV2-mediated suppression of NRF2-signaling reveals potent antiviral and antiinflammatory activity of 4-octyl-itaconate and dimethyl fumarate

Discovery of natural flavonoids as activators of Nrf2-mediated defense system: Structure-activity relationship and inhibition of intracellular oxidative insults

Isoflavone biochanin A, a novel nuclear factor erythroid 2-related factor 2 (Nrf2)-antioxidant response element activator, protects against oxidative damage in HepG2 cells

The Protective Effect of the Total Flavonoids of Abelmoschus esculentus L. Flowers on Transient Cerebral Ischemia-Reperfusion Injury Is due to Activation of the Nrf2-ARE Pathway

Cyanidin Chloride Induces Apoptosis by Inhibiting NF-κB Signaling through Activation of Nrf2 in Colorectal Cancer Cells

Transcription Factor Nrf2 as a Potential Therapeutic Target for Prevention of Cytokine Storm in COVID-19 Patients

Xanthohumol ameliorates lipopolysaccharide (LPS)-induced acute lung injury via induction of AMPK/GSK3β-Nrf2 signal axis

EGCG protects endothelial cells against PCB 126-induced inflammation through inhibition of AhR and induction of Nrf2-regulated genes

Protective action of Crateva nurvala Buch. Ham extracts against renal ischaemia reperfusion injury in rats via antioxidant and anti-inflammatory activities

Flavonoids from Apios americana Medikus Leaves Protect RAW264.7 Cells against Inflammation via Inhibition of MAPKs, Akt-mTOR Pathways, and Nfr2 Activation

DMO-CAP inhibits influenza virus replication by activating heme oxygenase-1-mediated IFN response

The anti-inflammatory action of nepitrin, a flavonoid

Hesperidin Suppresses Renin-Angiotensin System Mediated NOX2 Over-Expression and Sympathoexcitation

Hypertensive Rats

Tangeretin mitigates l-NAME-induced ventricular dysfunction and remodeling through the AT1R/pERK1/2/pJNK signaling pathway in rats

Kaempferol Prevents Against Ang IIinduced Cardiac Remodeling Through Attenuating Ang II-induced Inflammation and Oxidative Stress

COVID-19 and comorbidities: A role for dipeptidyl peptidase 4 (DPP4) in disease severity?

Anti-inflammatory properties of antidiabetic drugs: A "promised land" in the COVID-19 era?

Coronavirus infections and type 2 diabetes-shared pathways with therapeutic implications

Inflammation: A bridge between diabetes and COVID-19, and possible management with sitagliptin

Evaluation of the Anti-Diabetic Activity of Some Common Herbs and Spices: Providing New Insights with Inverse Virtual Screening

Grape seed-derived procyanidins decrease dipeptidyl-peptidase 4 activity and expression

A grape seed extract increases active glucagon-like peptide-1 levels after an oral glucose load in rats

Dipeptidyl Peptidase-4 Is a Target Protein of Epigallocatechin-3-Gallate

Citrus bioflavonoids dipeptidyl peptidase-4 inhibition compared with gliptin antidiabetic medications

Inhibitory effect of chestnut (Castanea mollissima Blume) inner skin extract on the activity of α-amylase, α-glucosidase, dipeptidyl peptidase IV and in vitro digestibility of starches

Structure-Activity Relationship and Molecular Docking of Natural Product Library Reveal Chrysin as a Novel Dipeptidyl Peptidase-4 (DPP-4) Inhibitor: An Integrated In Silico and In Vitro Study

Binding interaction of quercetin-3-β-galactoside and its synthetic derivatives with SARS-CoV 3CLpro: Structure-activity relationship studies reveal salient pharmacophore features

Inhibition of SARS-CoV 3CL protease by flavonoids

Characteristics of flavonoids as potent MERS-CoV 3C-like protease inhibitors

Structural stability of SARS-CoV-2 3CLpro and identification of quercetin as an inhibitor by experimental screening

In-silico screening of plantderived antivirals against main protease, 3CLpro and endoribonuclease, NSP15 proteins of SARS-CoV-2

Quercetin Phytosome® as a potential drug for Covid-19

Flavonoid glycosides and their putative human metabolites as potential inhibitors of the SARS-CoV-2 main protease (Mpro) and RNA-dependent RNA polymerase (RdRp)

Flavonoids and gut health

Flavonoids and the gastrointestinal tract: Local and systemic effects

Hesperidin Effects on Gut Microbiota and Gut-Associated Lymphoid Tissue in Healthy Rats

Flavonoids as anti-inflammatory agents

Intracellular signaling pathways of inflammation modulated by dietary flavonoids: The most recent evidence

Flavonoid Bioavailability and Attempts for Bioavailability Enhancement

Flavonoid intake is associated with lower mortality in the Danish Diet Cancer and Health Cohort

Dietary Quercetin and Kaempferol: Bioavailability and Potential Cardiovascular-Related Bioactivity in Humans

Role of Intestinal Microbiota in the Bioavailability and Physiological Functions of Dietary Polyphenols

The Bioavailability, Transport, and Bioactivity of Dietary Flavonoids: A Review from a Historical Perspective

All authors declare that they have no conflict of interest.